An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice

Ovarian cancer patients with germline or somatic pathogenic variants benefit from treatment with poly ADP ribose polymerase (PARP) inhibitors. Tumor BRCA1/2 testing is more challenging than germline testing as the majority of samples are formalin‐fixed paraffin embedded (FFPE), the tumor genome is c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellison, Gillian, Ahdesmäki, Miika, Luke, Sally, Waring, Paul M., Wallace, Andrew, Wright, Ronnie, Röthlisberger, Benno, Ludin, Katja, Merkelbach‐Bruse, Sabine, Heydt, Carina, Ligtenberg, Marjolijn J.L., Mensenkamp, Arjen R., de Castro, David Gonzalez, Jones, Thomas, Vivancos, Ana, Kondrashova, Olga, Pauwels, Patrick, Weyn, Christine, Hahnen, Eric, Hauke, Jan, Soong, Richie, Lai, Zhongwu, Dougherty, Brian, Carr, T. Hedley, Johnson, Justin, Mills, John, Barrett, J. Carl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838520/
https://www.ncbi.nlm.nih.gov/pubmed/29215764
http://dx.doi.org/10.1002/humu.23375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838520/
https://www.ncbi.nlm.nih.gov/pubmed/29215764
http://dx.doi.org/10.1002/humu.23375

Ejemplares similares